US 12,084,476 B2
Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors
Markus Kaiser, Essen (DE); Steffen Köcher, Essen (DE); Juliana Rey, Essen (DE); Jens Bongard, Essen (DE); Michael Ehrmann, Essen (DE); and Sarah Resch, Essen (DE)
Assigned to UNIVERSITÄT DUISBURG-ESSEN, Essen (DE)
Filed by UNIVERSITÄT DUISBURG-ESSEN, Essen (DE)
Filed on Sep. 15, 2021, as Appl. No. 17/476,041.
Application 17/476,041 is a division of application No. 16/610,171, granted, now 11,149,067, previously published as PCT/EP2018/062381, filed on May 14, 2018.
Claims priority of application No. LU100200 (LU), filed on May 12, 2017.
Prior Publication US 2022/0002348 A1, Jan. 6, 2022
Int. Cl. C07K 11/02 (2006.01); A61K 38/00 (2006.01); C07K 1/10 (2006.01); C12Q 1/37 (2006.01)
CPC C07K 11/02 (2013.01) [C07K 1/10 (2013.01); C12Q 1/37 (2013.01); A61K 38/00 (2013.01); G01N 2500/04 (2013.01)] 9 Claims
 
1. An Ahp-cyclodepsipeptide having the following formula

OG Complex Work Unit Chemistry
wherein
P1 is an α-amino acid with a cyclopropyl group as side chain;
P2 is an amino acid with a hydroxyl group in the side chain;
P3 is any amino acid;
P4 is any amino acid
P1′ is 5-hydroxy-norvaline forming a 3-amino-6-hydroxy-2-piperidone unit with the α-amino group of P2′;
P2′ is any amino acid;
P3′ is an amino acid with a hydrophobic side chain comprising a methyl group attached to the α-amino group;
Px is any amino acid coupled with its α-carboxylic acid group to the hydroxyl group of P2, forming an ester bond;
R is hydrogen or a chemical group.